Safety and efficacy of tisagenlecleucel plus pembrolizumab in patients with r/r DLBCL: phase 1b PORTIA study results
Sign Up to like & getrecommendations! Published in 2022 at "Blood Advances"
DOI: 10.1182/bloodadvances.2022007779
Abstract: Key Points • The best response rates were observed with pembrolizumab before tisagenlecleucel; however, definitive conclusions cannot be made.• Pembrolizumab did not augment the cellular expansion of tisagenlecleucel but delayed peak expansion in the day… read more here.
Keywords: tisagenlecleucel plus; pembrolizumab patients; plus pembrolizumab; safety efficacy ... See more keywords